Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis (MSECP)
A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)
Sponsor: Mallinckrodt
Terminated
Low enrollment/PI relocated. New site couldn't reach agreement with manufacturer
Listed as NCT02296346, this NA trial focuses on Secondary Progressive Multiple Sclerosis and remains terminated or withdrawn. Sponsored by Mallinckrodt, it has been updated 10 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Dec 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Sep 2019 — Jan 2021 [monthly]
Terminated NA
Status: Suspended → Terminated · Phase: PHASE1 → NA
-
Jun 2018 — Sep 2019 [monthly]
Suspended PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mallinckrodt
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .